AbbVie Inc

ABBVHealthcare

Sentinellis Health Score

7.4/10

Financially healthy
Market Cap

$377.7B

Revenue

$61.2B

P/E Ratio

105.3x

AI Summary

AbbVie researches, develops, and sells prescription medicines across multiple therapeutic areas. Their biggest focus is immunology drugs (like Skyrizi and Rinvoq) that treat autoimmune diseases, along with cancer treatments (Imbruvica, Venclexta), neuroscience medications (Vraylar, Botox, migraine drugs), and aesthetics products (facial injectables and skincare) [Yahoo Finance]. The company also sells eye care products and treatments for digestive conditions.

AbbVie is a large pharmaceutical company headquartered in Illinois that develops and sells medicines for serious diseases including autoimmune conditions, cancer, neurological disorders, and eye diseases [Yahoo Finance]. The company spun off from Abbott Laboratories in 2013 and now employs 57,000 people worldwide, generating $61.2 billion in annual revenue [Yahoo Finance]. AbbVie is successfully transitioning away from its former blockbuster drug Humira by growing newer products like Skyrizi, Rinvoq, and neuroscience treatments [Yahoo Finance].

AbbVie is financially healthy with strong cash generation, though it carries moderate debt and trades at an unusually high valuation [Yahoo Finance].

Confidence8/10

Recent News

  • Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

    Zacks· 2026-05-19
  • Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols

    Yahoo Finance· 2026-05-18
  • Polymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer

    Yahoo Finance· 2026-05-19
  • 2 Reasons to Like ABBV and 1 to Stay Skeptical

    Yahoo Finance· 2026-05-19
  • Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth

    Yahoo Finance· 2026-05-18
  • Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by 2032 from $4.7 Billion in 2025 Featuring AbbVie, Aphria, Aurora Cannabis, Bausch Health, and Canopy Growth

    Yahoo Finance· 2026-05-18

Risk Analysis

Opportunities

Full Financials

Executive Team

Unlock the full AbbVie Inc analysis

Create a free account to access the complete AI-generated report with inline citations.

  • Risks, opportunities, and red flags with sources
  • 100+ financial metrics with charts and benchmarks
  • Full news summaries with source links
  • Executive team and compensation details
  • PDF export for offline use
Get my free report3 free reports · No credit card

Other companies you might find interesting

Same sector (Healthcare) or comparable health.